Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

NCT ID: NCT01658904

Last Updated: 2016-06-01

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 3 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-07-31
• Study Completion Date: 2014-04-30

Brief Summary

Background:

• Plasma cell myeloma is a type of cancer that affects the plasma cells in the bone marrow. It can be difficult to treat with chemotherapy. One possible treatment combines chemotherapy with a stem cell transplant. To make this treatment more effective, researchers want to give another drug along with the transplant. This drug, carfilzomib, is often used to help treat plasma cell myeloma. However, it is not usually given along with the transplant. Researchers want to see if it is safe and effective to combine the stem cell transplant with carfilzomib, and if it improves the results of the transplant.

Objectives:

• To test the safety and effectiveness of carfilzomib given with stem cell transplant for plasma cell myeloma.

Eligibility:

• Individuals between 18 and 75 years of age who are having a stem cell transplant to treat plasma cell myeloma.

Design:

• Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies and a bone marrow biopsy will also be performed.
• Participants will have their own stem cells collected for the transplant. The transplant will be performed according to the standard of care.
• All participants will receive carfilzomib on the first 2 days after transplant. The study doctors will determine the number of additional doses that they may have.
• Treatment will be monitored with frequent blood tests and imaging studies.

Detailed Description

Background:

• Despite very significant progress in therapy for plasma cell myeloma (PCM) in the last decade, the disease remains mostly incurable.
• High-dose chemotherapy followed by autologous hematopoietic cell transplantation (AHCT) continues to be a critical component of early treatment for PCM, but it is clear that the disease is not eradicated by the present high-dose therapy strategy, while intensifying the preparative regimen has, to this day, resulted in either no improvement in disease control or increased toxicity.
• Carfilzomib (CFZ) is a newer proteasome inhibitor with increased activity and a safer toxicity profile than bortezomib in PCM. The favorable toxicity profile makes it a likely candidate for increasing anti-PCM drug exposure in the early post-AHCT period.

Objectives:

Primary Objectives

-Evaluate feasibility and toxicity of an increasing number of doses of CFZ administered in the early period post-AHCT for PCM

Secondary Objective

• Evaluate the immune reconstitution post-AHCT following CFZ therapy
• Evaluate the effects of the addition of CFZ in the early post-AHCT period on the response rate at day 100 post-AHCT

Eligibility:

• Newly diagnosed subjects with PCM following induction therapy
• Subjects with documentation of persistent/refractory disease who have received no more than 2 salvage regimens following relapse and who have not undergone AHCT
• Adequate organ functions with no major co-morbidity
• Age greater than 18 years and less than or equal to 75 years

Design:

• Phase I/II study on the backbone of high-dose melphalan on day -2 pre-AHCT
• Addition of an increasing number of doses of CFZ in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:

Cohort 1: add CFZ 20 mg/m^2 on days +1, +2

Cohort 2 : add CFZ 20 mg/m^2 on days: +1, +2, +8, +9

Cohort 3: add CFZ 20 mg/m^2 on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following

engraftment: CFZ 20 mg/m^2 given on days 42-43 then CFZ 56 mg/m^2 given on days 49-50, 56-57, then on days 70-71, 77-78 and 84-85

-Dose-limiting toxicity, incidence of engraftment failure and treatment-related mortality are the objects of early stopping rules for safety purposes

Conditions

Multiple Myeloma; Leukemia, Plasma Cell

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1- CFZ 20 mg/m^2 (Day 1,2)

Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)

•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:

Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2

Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9

Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.

Group Type: EXPERIMENTAL

Carfilzomib

Intervention Type: DRUG

Melphalan

Intervention Type: DRUG

Filgrastim

Intervention Type: DRUG

Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)

Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)

•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:

Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2

Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9

Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.

Group Type: EXPERIMENTAL

Carfilzomib

Intervention Type: DRUG

Melphalan

Intervention Type: DRUG

Filgrastim

Intervention Type: DRUG

Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)

Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)

•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:

Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2

Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9

Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.

Group Type: EXPERIMENTAL

Carfilzomib

Intervention Type: DRUG

Melphalan

Intervention Type: DRUG

Filgrastim

Intervention Type: DRUG

Interventions

Carfilzomib

Intervention Type: DRUG

Melphalan

Intervention Type: DRUG

Filgrastim

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Multiple myeloma criteria for newly or recently diagnosed subjects

• Presence of clonal plasma cells in the bone marrow greater than or equal to 10% or a documented clonal plasmacytoma (either by immuno-histochemistry or by Ig gene rearrangement), AND
• Presence of an M-component; an M-component (immunoglobulin G (IgG) or immunoglobulin A (IgA)) in serum greater than or equal to 1g/dl or in urine greater or equal to 200 mg/24 h.

ALTERNATIVELY, if the M-component criterion is not met:

• An abnormal serum free light chain (FLC) ratio on the serum FLC assay, or if the FLC ratio is normal,
• Baseline bone marrow must have 10% or greater clonal plasma cells

AND, IN ADDITION, presence of one or more of the following attributable to the disease (in the presence or absence of an M-component):

• Calcium elevation greater than 11.5 mg/dl (2.65 mmol/l)
• Renal insufficiency: serum creatinine greater than 2 mg/dl (177 mmol/l) or less than 60ml/min.
• Hemoglobin less than 10 g/dl (12.5 mmol/l) or 2 g/dl (1.25 mmol/l) below lower normal
• Bone disease (lytic lesions or osteopenia)
• Other evidence of disease activity: repeated infections, secondary amyloidosis, hyperviscosity, hypogammablobulinemia

Criteria for subjects with persistent or recurrent disease

Subjects with recurrent or persistent disease are eligible if:

• Criteria for initiating therapy for plasma cell myeloma (PCM) had been present at the time of initiation of therapy or there is clear clinical indication for salvage therapy.
• They have not undergone an autologous transplant for the treatment of PCM
• They have received no more than two salvage regimens for the treatment of recurrent or persistent PCM (each regimen may include more than one cycle)

Other eligibility criteria

-Age > 18 years and less than or equal to 75 years.

Exclusion Criteria

• Karnofsky performance status of 70% or greater (Eastern Cooperative Oncology Group (ECOG) 0 or 1)
• Ejection fraction (EF) by multi-gated acquisition scan (MUGA) or 2-D echocardiogram within institution normal limits. In case of low ejection fraction (EF), the subject may remain eligible after a stress echocardiogram is performed if the EF is more than 35% and if the increase in EF with stress is estimated at 10% or more.
• creatinine clearance > 25ml/min (measured on a 24 hour urine collection)
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x upper limit of normal
• Bilirubin less than or equal to1.5 (except if due to Gilbert's disease)
• Corrected carbon dioxide diffusing capacity (DLCO) greater than or equal to 40% on pulmonary function tests

• Prior allogeneic or autologous stem cell transplantation
• Prior treatment with Carfilzomib (CFZ) is not an exclusion
• History of recent (< 6 months) cerebrovascular accident
• History of documented recent (< 6 months) pulmonary embolus
• Clinically significant cardiac pathology:
• Myocardial infarction within 6 months prior to enrollment,
• Class III or IV heart failure according to New York Heart Association (NYHA),
• Uncontrolled angina,
• Severe uncontrolled ventricular arrhythmias, or
• Electrocardiographic evidence of acute ischemia or active conduction abnormalities felt to pose a significant cardiac riks by a Cardiology consultant
• Patients with a history of coronary artery bypass grafting or angioplasty will receive a cardiology evaluation and be considered on a case-by-case basis.
• Human immunodeficiency virus (HIV) seropositive
• Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to enrollment
• Active hepatitis B or C infection
• Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment
• Major surgery within 21 days prior to enrollment
• Non-hematologic malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas
• Significant neuropathy (Grades 3 4, or Grade 2 with pain) within 14 days prior to randomization
• Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize CFZ)
• Patients known or found to be pregnant
• Female patients of childbearing age who are unwilling to practice contraception
• Patients may be excluded at the discretion of the principal investigator (PI) if it is deemed that allowing participation would represent an unacceptable medical or psychiatric risk.
• Patients must be able to give informed consent

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Responsible Party

Daniel Fowler, M.D.

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Ronald E Gress, M.D.

Role: PRINCIPAL_INVESTIGATOR

National Cancer Institute (NCI)

Locations

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, United States

Countries

United States

References

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.

Reference Type: BACKGROUND

PMID: 18287387 (View on PubMed)

Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006 Jan 20;24(3):431-6. doi: 10.1200/JCO.2005.03.0221. Epub 2005 Dec 19.

Reference Type: BACKGROUND

PMID: 16365178 (View on PubMed)

Tosi P, Zamagni E, Cellini C, Plasmati R, Cangini D, Tacchetti P, Perrone G, Pastorelli F, Tura S, Baccarani M, Cavo M. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol. 2005 Mar;74(3):212-6. doi: 10.1111/j.1600-0609.2004.00382.x.

Reference Type: BACKGROUND

PMID: 15693790 (View on PubMed)

Other Identifiers

12-C-0179

Identifier Type: -

Identifier Source: secondary_id

120179

Identifier Type: -

Identifier Source: org_study_id